Tobias Welte
Expertise in
39
conditions

Tobias Welte

Carl Neuberg Str. 1, 
Hannover, NI, DE 
Expertise in
39
conditions
Carl Neuberg Str. 1, 
Hannover, NI, DE 

Overview

Tobias Welte practices practicing medicine in Hannover, Germany.

Mr. Welte is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Pneumonia, Chronic Obstructive Pulmonary Disease (COPD), Bronchiectasis, Lung Transplant, and Endoscopy.

He is actively involved in clinical research, co-authoring 739 peer reviewed articles and participating in 8 clinical trials.

Gender

Male

Locations

Carl Neuberg Str. 1, Hannover, NI 30625, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Triple thErapy in paTients With COPD Under Real lIve Setting (the TETRIS Study)
Triple thErapy in paTients With COPD Under Real lIve Setting (the TETRIS Study)
Enrollment Status: Completed
Publish Date: August 17, 2025
Intervention Type: Other
GM-CSF Inhalation to Improve Host Defense and Pulmonary Barrier Restoration (GI-HOPE). A Randomized, Double-blind, Parallel Group, Multicenter, Phase II Study
GM-CSF Inhalation to Improve Host Defense and Pulmonary Barrier Restoration (GI-HOPE). A Randomized, Double-blind, Parallel Group, Multicenter, Phase II Study
Enrollment Status: Completed
Publish Date: August 31, 2023
Intervention Type: Drug
Study Drug: Molgramostim
Study Phase: Phase 2
Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Inhalation to Prevent ARDS in COVID-19 Pneumonia (GI-COVID)
Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Inhalation to Prevent ARDS in COVID-19 Pneumonia (GI-COVID)
Enrollment Status: Completed
Publish Date: May 10, 2023
Intervention Type: Drug, Other
Study Drug: Molgramostim
Study Phase: Phase 2
A Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-814 in PiZZ Subjects
A Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-814 in PiZZ Subjects
Enrollment Status: Terminated
Publish Date: February 02, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Multi-centre, Open-label Extension, Safety Study to Describe the Long-term Clinical Experience of Mepolizumab in Participants With Hypereosinophilic Syndrome (HES) From Study 200622
A Multi-centre, Open-label Extension, Safety Study to Describe the Long-term Clinical Experience of Mepolizumab in Participants With Hypereosinophilic Syndrome (HES) From Study 200622
Enrollment Status: Completed
Publish Date: June 23, 2020
Intervention Type: Drug
Study Phase: Phase 3
Randomized Double Blind Placebo-controlled Study to Demonstrate That Antibiotics Are Not Needed in Moderate Acute Exacerbations of COPD - The ABACOPD Study
Randomized Double Blind Placebo-controlled Study to Demonstrate That Antibiotics Are Not Needed in Moderate Acute Exacerbations of COPD - The ABACOPD Study
Enrollment Status: Completed
Publish Date: June 05, 2020
Intervention Type: Drug
Study Phase: Phase 4
Early Oral Switch Therapy in Low-risk Staphylococcus Aureus Bloodstream Infection
Early Oral Switch Therapy in Low-risk Staphylococcus Aureus Bloodstream Infection
Enrollment Status: Completed
Publish Date: May 27, 2020
Intervention Type: Drug
Study Phase: Phase 3
Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous ΔF508 Cystic Fibrosis
Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous ΔF508 Cystic Fibrosis
Enrollment Status: Completed
Publish Date: February 06, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 7 Less Clinical Trials

739 Total Publications

Management of Adult Bronchiectasis - Consensus-based Guidelines of the German Respiratory Society.
Management of Adult Bronchiectasis - Consensus-based Guidelines of the German Respiratory Society.
Journal: Respiration; international review of thoracic diseases
Published: February 16, 2026

Frequently Asked Questions about Tobias Welte

Is Tobias Welte a top-rated expert for Pneumonia?

MediFind is an objective health platform that identifies experts based on real-world data. Tobias Welte is classified as an Elite expert for Pneumonia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Tobias Welte participate in research or clinical trials?

Yes. Tobias Welte has published 739 articles and abstracts on conditions like Pneumonia. You can view a list of Tobias Welte's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Welte's expertise for a condition
ConditionClose
View All 8 Elite Conditions
View All 17 Distinguished Conditions
View All 14 Advanced Conditions
View All 59 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile